five. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal (2010) 12:13. doi:10.1089/ars.2008.2282 Mikami Y, Shibuya N, Kimura Y, Nagahara N, Yamada M, Kimura H. Hydrogen sulfide protects the retina from lightinduced degeneration by the modulation of Ca2+ influx. J Biol Chem (2011) 286:393796. doi:10.1074/jbc.M111.298208 Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A (2007) 104:15560. doi:ten.1073/pnas.0705891104 19. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, et al. Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest (2008) 88:10388. doi:10.1038/labinvest.2008.73 20. Stipanuk MH, Beck PW. Characterization with the enzymic capacity for cysteine desulphhydration in liver and kidney in the rat. Biochem J (1982) 206: 2677. 21. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur inside the brain. Antioxid Redox Signal (2009) 11:7034. doi:ten.1089/ARS.2008.2253 22. Singh S, Padovani D, Leslie RA, Chiku T, Banerjee R. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2 S biogenesis through alternative transsulfuration reactions. J Biol Chem (2009) 284:224576. doi:10.1074/jbc.M109.010868 18.
Effectiveness of Key Anti-Aspergillus Prophylaxis through Remission Induction Chemotherapy of Acute Myeloid LeukemiaMarisa Z.Gemtuzumab R. Gomes,a,b Ying Jiang,a Victor E. Mulanovich,a Russell E. Lewis,a* Dimitrios P. KontoyiannisaDepartment of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Texas, USAa; Nosocomial Infection Analysis Laboratory, Instituto Oswaldo Cruz, Funda o Oswaldo Cruz, Rio de Janeiro, BrazilbAlthough antifungal prophylaxis is regularly administered to individuals with acute myeloid leukemia (AML) through remissioninduction chemotherapy (RIC), its influence on reducing invasive fungal infections (IFIs) outside clinical trials is rarely reported.Emodin We performed a retrospective observational study to identify risk factors for improvement of IFIs (definite or probable, applying revised European Organization for Analysis and Remedy of Cancer [EORTC] criteria) and all-cause mortality in a cohort of 152 AML individuals receiving RIC (2009 to 2011).PMID:24580853 We also compared rates of IFI and mortality in patients who received echinocandin versus anti-Aspergillus azole (voriconazole or posaconazole) prophylaxis through the initially 120 days of RIC. In multivariate analysis, clofarabine-based RIC (hazard ratio [HR], three.five; 95 self-confidence interval [CI], 1.5 to eight.3; P 0.004) and echinocandin prophylaxis (HR, 4.6; 95 CI, 1.eight to 11.9; P 0.002) have been independently linked with larger rates of IFI prices through RIC. Subsequent analysis failed to identify any malignancy- or chemotherapy-related covariates linked to echinocandin prophylaxis that accounted for the higher rates of breakthrough IFI. Though the possibility of other confounding variables can’t be excluded, our findings suggest that echinocandin-based prophylaxis through RIC for AML may very well be linked with a greater threat of breakthrough IFI.atients with acute myeloid leukemia (AM.